Ameriprise Financial Inc. Has $82.01 Million Stake in Charles River Laboratories International, Inc. $CRL

Key Points

• Ameriprise Financial Inc. increased its holdings in Charles River Laboratories International by 144.3%, now owning a total of 544,825 shares worth approximately $82 million.
• Multiple hedge funds also increased their positions in Charles River Laboratories, contributing to institutional investors owning 98.91% of the company's stock.
• The company's recent earnings report showed a positive earnings per share of $3.12, exceeding expectations and reflecting a year-over-year revenue increase of 0.6%.

Ameriprise Financial Inc. boosted its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 144.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 544,825 shares of the medical research company's stock after buying an additional 321,789 shares during the quarter. Ameriprise Financial Inc. owned approximately 1.11% of Charles River Laboratories International worth $82,007,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Wahed Invest LLC boosted its stake in Charles River Laboratories International by 6.5% in the 4th quarter. Wahed Invest LLC now owns 1,321 shares of the medical research company's stock valued at $244,000 after buying an additional 81 shares in the last quarter. Two Sigma Securities LLC boosted its stake in Charles River Laboratories International by 4.3% in the 4th quarter. Two Sigma Securities LLC now owns 1,981 shares of the medical research company's stock valued at $366,000 after buying an additional 81 shares in the last quarter. Brooklyn Investment Group boosted its stake in Charles River Laboratories International by 93.5% in the 1st quarter. Brooklyn Investment Group now owns 178 shares of the medical research company's stock valued at $27,000 after buying an additional 86 shares in the last quarter. Teachers Retirement System of The State of Kentucky boosted its stake in Charles River Laboratories International by 2.7% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 3,916 shares of the medical research company's stock worth $589,000 after purchasing an additional 102 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Charles River Laboratories International by 2.6% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,131 shares of the medical research company's stock worth $763,000 after purchasing an additional 105 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 800 shares of the business's stock in a transaction on Monday, August 18th. The stock was sold at an average price of $157.60, for a total transaction of $126,080.00. Following the completion of the sale, the executive vice president owned 24,116 shares in the company, valued at $3,800,681.60. The trade was a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Trading Up 0.0%

Shares of CRL stock traded up $0.07 on Friday, reaching $163.29. 860,239 shares of the stock were exchanged, compared to its average volume of 956,203. The stock has a market cap of $8.04 billion, a PE ratio of -122.77, a P/E/G ratio of 5.22 and a beta of 1.47. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $230.02. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.36 and a quick ratio of 1.10. The stock has a 50 day moving average price of $159.32 and a 200 day moving average price of $148.75.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share for the quarter, topping analysts' consensus estimates of $2.50 by $0.62. The company had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $983.76 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The firm's quarterly revenue was up .6% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.80 earnings per share. Equities research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have commented on CRL shares. Redburn Atlantic raised Charles River Laboratories International from a "neutral" rating to a "buy" rating and reduced their price objective for the stock from $188.00 to $182.00 in a research note on Friday, May 23rd. JPMorgan Chase & Co. boosted their price objective on Charles River Laboratories International from $145.00 to $160.00 and gave the stock a "neutral" rating in a research note on Thursday, August 7th. TD Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price objective on the stock in a research note on Wednesday, May 14th. Barclays boosted their price objective on Charles River Laboratories International from $155.00 to $165.00 and gave the stock an "equal weight" rating in a research note on Thursday, August 7th. Finally, Robert W. Baird boosted their price objective on Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a research note on Thursday, May 8th. Five investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Charles River Laboratories International presently has an average rating of "Hold" and a consensus target price of $175.69.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).